VAP-Measured Lipid Subfractions and In-Stent Restenosis After PCI

Condition(s) studied

Investigational drug(s) / intervention(s)

No intervention: Observational study only. Participants receive standard clinical care. Serum samples from routine clinical blood collection are used for VAP testing without additional study-specific intervention.

Study summary

This multicenter observational study investigates whether lipid and lipoprotein subfractions measured by Vertical Auto Profile (VAP) are associated with coronary in-stent restenosis after percutaneous coronary intervention (PCI). The study includes a retrospective cross-sectional component in patients with prior PCI who undergo repeat coronary angiography and a prospective follow-up component in patients undergoing index PCI. Serum samples obtained from routine clinical blood collection will be used for VAP testing without additional blood draws.

Eligibility

Primary outcome measure(s)

• Presence of angiographic in-stent restenosis in the retrospective cross-sectional cohort — At repeat coronary angiography, more than 6 month after prior PCI
  In-stent restenosis is defined as \>=50% luminal stenosis in the stent-related lumen at repeat coronary angiography.
• Occurrence of angiographic in-stent restenosis in the prospective cohort — At follow-up coronary angiography, up to 12 months after index PCI
  In-stent restenosis is defined as \>=50% luminal stenosis in the stent-related lumen at follow-up coronary angiography.
• Target lesion revascularization in the prospective cohort — Within 12 months after index PCI
  Target lesion revascularization related to prior stent restenosis requiring repeat PCI or CABG.

Trial sites (1)

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition